760 Subject Index
seemethanandamide
seenabilone
seeR-(+)-WIN55212
SAR 212–222, 226–231, 233–
236, 250, 251
cannabinoid receptor antgonists
AM251 10,21–23,31,434,613,
616, 617
AM281 10, 21–23, 30, 435
AM630 10, 22–24, 32, 617
seeLY320135
seeSR141716
seeSR144528
SAR 223–225, 231, 2332, 251,
252
cannabinoid receptor during devel-
opment 645–648, 652
atypical localization of 646,
652
CB 1 receptor oligomerization 38
cannabinol 8, 13, 17, 31
cannabis withdrawal 698
abstinence withdrawal 700
anandamide 703
antidepressants 707
bupropion 707, 708
clonidine 707
CP 55,940 703
divalproex 707, 708
dogs 701, 702
fluoxetine (Prozac) 708
HU-210 703
inpatient 698
knockout mice 706
naloxone 707
naltrexone 709
nefazodone 707, 708
outpatient 698
precipitated withdrawal 700
retrospective 698
Serzone 707
THC 703, 709
WIN 55,212-2 703
withdrawal effects 699
Zyban 707
capsaicin 26, 28, 30, 31, 33, 609,
613, 614
capsazepine 30–33, 609, 610, 613–
615
cardiac contractility 600, 604, 613,
615, 616
cardiac output 604, 605, 613
cardioprotection 617
cardiovascular effects/responses
124, 739
cartilaginous fish 290
caspase 392
caudateputamen 332,333,337,338,
343, 351
striatonigral 311
striatopallidal 311
CB 2 -like receptors 27, 28, 32
CCK
perforant path 310
cell death 627
cell proliferation 628
cephalochordates 285, 290, 291
cerebellar 288
cerebellar ataxia 355
cerebellar cortex 355
cerebellum 334, 337, 339, 343, 431,
468
basket cells 316
climbing fibers 316
granule cell 316
molecular layer 316
parallel fibers 316
Purkinje cell 316
cerebral blood flow 449
cerebral glucose utilization 694
CGRP seecalcitonin gene-related
peptide
Chlamydia 404
Chlamydia trachomatis 402
cholecystokinin 303
cholera toxin 574, 576, 588
cholinergicmyentericmotorneurons
stomach 319
vagal afferents 319
chordates 291
chronic pain 729